Built on MVE’s legacy SC 4/2V and 4/3V vapor shipper platform, the next-generation SC 4/2V and 4/3V models have been ...

Celltrion USA announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo), biosimilars referencing Prolia ...

Centauri Therapeutics Limited, an immunotherapy company, has appointed Dr. Debra Barker as Chief Medical Officer (CMO).

Dr. Richard Philipson has been appointed Chief Medical Officer (CMO) of Hansa Biopharma AB, effective July 14.

Gusacitinib was acquired by Formation Bio in late 2022 from Asana BioSciences as part of a broader portfolio of investigational medicines. This transaction with Sanofi ushers gusacitinib into its next ...

“The addition of Agilera’s capabilities to PharmaLogic marks a key milestone in our expansion strategy into radiopharmaceutical therapeutics,” said Etienne Montagut, President and CEO of PharmaLogic. ...

The site will now incorporate a further 26,000 square feet of drug substance manufacturing suites, laboratories, storage, dispensing, and warehousing. As well as conventional fed-batch drug substance ...

LOTTE BIOLOGICS will produce antibody drug substance for Ottimo Pharma’s Jankistomig at its Syracuse Bio Campus in New York. James Park, CEO of LOTTE BIOLOGICS, stated, “This agreement serves as ...

Bend Bioscience, has opened four new process development and manufacturing suites within its 30,000-sq.-ft. site in Bend, OR. The suites will support spray drying and unit operations including ...

Lifecore Biomedical (Lifecore), a fully integrated CDMO, has signed a new 10-year commercial manufacturing and supply agreement with a key existing customer. This represents the latest agreement ...

The all-stock transaction will bring together two complementary companies based in Germany and will build on BioNTech’s proven track record and established position in the global mRNA industry. With ...

Breaking News, Collaborations & Alliances Novo Nordisk Signs $800M+ Deal with Deep Apple Therapeutics for Obesity R&D Aims to discover, develop, and commercialize oral small molecule therapeutics ...